A Study of I-131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission.

Trial Profile

A Study of I-131-Tositumomab (Bexxar) Consolidation In Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma In First Remission.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs Iodine-131 tositumomab (Primary) ; Tositumomab (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Mar 2017 Status changed from active, no longer recruiting to terminated as per the results published in the Leukemia and Lymphoma.
    • 08 Mar 2015 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2015 as reported by ClinicalTrials.gov.
    • 11 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top